Searchable abstracts of presentations at key conferences on calcified tissues

ba0002p68 | (1) | ICCBH2013

Engineered tridimensional hydroxyapatite scaffold to support bone resorption

Cappariello Alfredo , Mirabile Eleonora , Muraca Maurizio , Teti Anna

Objective: In many traumatic or pathological conditions, bone turnover is low and osteoclast activity is reduced or abolished. We developed innovative hydroxyapatite (HA) scaffolds carrying RANKL expressing cells with the aim of supporting bone resorption when this is defective. Membrane-bound (m)RANKL is cleaved into soluble (s)RANKL by MMP14. We hypothesized that the osteoclastogenic potential of RANKL-producing cells could be improved if they were seeded on scaffolds engine...

ba0005p371 | Osteoporosis: pathophysiology and epidemiology | ECTS2016

Seasonal and environmental effect on the incidence of hip fractures and non hip fractures in Italy

Tarantino Umberto , Feola Maurizio , Rao Cecilia , Guazzini Andrea , Piscitelli Prisco

Background and objective: Data concerning the incidence of fractures in Italy have been displayed since year 2000 by analysing hospital discharge records (HDRs). However, the influence of seasonal and environmental factors on fracture events in the Italian population has not yet been assessed.Methods: We have analyzed HDRs for primary diagnosis of hip, vertebral, forearm, humeral and knee fractures in Italy from year 2007 to 2009. Inferential statistics ...

ba0001oc5.5 | Treatment of osteoporosis | ECTS2013

Bone anabolic efficacy and safety of ba058, a novel analog of hPTHrP: 12-month extension data from a phase 2 clinical trial in postmenopausal women with osteoporosis

Hattersley Gary , Bilezikian John , Guerriero Jonathan , Kumar Prasanna , Zanchetta Jose , Lyttle C Richard , O'Dea Louis Saint L

A randomized, placebo-controlled phase 2 study evaluated the safety and efficacy of BA058, an analog of hPTHrP(1–34), in postmenopausal women with severe osteoporosis. 221 patients were randomized to received BA058 20, 40, and 80 μg, placebo or teriparatide (TP) 20 μg, by daily s.c. injection. 184 (83%) patients completed an initial 24 weeks of treatment. The mean percent change in lumbar spine BMD at 24 weeks was 1.6% with placebo, 6.7% with BA058 80 μg, a...

ba0001oc6.2 | Mineralisation and energy metabolism | ECTS2013

Deficiency of the bone mineralisation inhibitor NPP1 protects against obesity and diabetes

Huesa Carmen , Morton Nicholas M , Ferron Mathieu , Karsenty Gerard , Millan Jose Luis , Ahmed Faisal , Farquharson Colin , MacRae Vicky E

Bone has recently emerged as a novel endocrine organ regulating glucose metabolism. Ectonucleotide pyrophosphatase/phosphodiesterase-1 (NPP1) controls bone mineralisation by generating the mineralisation inhibitor pyrophosphate. In clinical studies increased activity of NPP1 has been found in patients with insulin resistance, and it has been shown to directly inhibit the insulin receptor. We hypothesised that mice lacking NPP1 (Enpp1−/−) would exhibit im...

ba0001pp337 | Osteoporosis: evaluation and imaging | ECTS2013

Dietary calcium and vitamin D intake and serum 25-hydroxyvitamin D and parathyroid hormone levels in healthy elderly Spanish men: the relationship with calcaneal and phalangeal quantitative ultrasound and phalangeal dual energy X-ray absorptiometry

Leal Alejo , Luz Canal-Macias Maria , Fernando Calderon-Garcia Julian , Roncero-Martin Raul , Rodriguez-Dominguez Trinidad , Moran Jose M

Purpose: To evaluate whether calcium and vitamin D intake is associated with 25-hydroxyvitamin D (25(OH)D) and parathyroid hormone (PTH) serum concentrations or is associated with either the phalangeal dual energy X-ray absorptiometry (pDXA) or the quantitative bone ultrasound (QUS) at the phalanges and the calcaneus in independent elderly men from southwestern Spain.Methods: Serum PTH and 25(OH)D were measured in 199 healthy elderly men (mean age: 73.31...

ba0002p181 | (1) | ICCBH2013

Long-term imiglucerase/alglucerase treatment in Latin American children with type 1 Gaucher disease: lessons from the International Collaborative Gaucher Group (ICGG) Gaucher Registry

Camelo Jr Jose Simon , Cabello Juan Francisco , Drelichman Guillermo G , Kerstenetzky Marcelo M , Sarmiento Isabel C , Linares Adriana

Objective: Evaluate the clinical characteristics of all Latin American pediatric patients with Gaucher disease type 1 (GD1) enrolled in the ICGG Gaucher Registry at baseline and investigate long-term outcomes and clinical benefit of prolonged imiglucerase/alglucerase therapy in patients with manifestations of GD1 at baseline.Methods: All Latin American patients with GD1 in the ICGG Gaucher Registry (NCT00358943) who were <18 years of age at the start...

ba0003pp320 | Osteoporosis: treatment | ECTS2014

Effects of preventive long-term treatment with strontium ranelate and zoledronic acid to ovariectomized rats on bone microstructure

Martin-Fernandez Marta , Gomez-Chinchon Marina , Guede David , Caeiro Jose Ramon , Diaz-Curiel Manuel , De la Piedra Concepcion

Many pharmacological treatments have been developed in order to prevent or treat postmenopausal osteoporosis. There is not any study in the literature comparing long-term treatments of osteoporosis. The aim of this work was to studythe effects of long-term prevention treatment with zoledronic acid (ZA) and strontium ranelate (SrR) on bone microstructure in ovariectomized rats.Sixty 6-month-old female Wistar rats were used in this study and divided into f...

ba0005p60 | Bone development/growth and fracture repair | ECTS2016

Role of PHOSPHO1 in chondrocyte matrix vesicle mineralization: an AFM study

Bottini Massimo , Yadav Manisha , Bhattacharya Kunal , Magrini Andrea , Rosato Nicola , Fadeel Bengt , Farquharson Colin , Luis Millan Jose

We used atomic force microscopy (AFM) to study the morphology and development of mineralization-competent matrix vesicles (MVs) secreted by chondrocytes isolated from WT and Phospho1−/− mice in order to validate the role of PHOSPHO1 in MV mineralization. All MVs appeared as flattened globular features either individually dispersed or connected to a mat-like structure. The mat-like structure very closely resembled type-X collagen that has been de...

ba0005p73 | Bone development/growth and fracture repair | ECTS2016

Combination of novel two-photon photopolymerised scaffolds and bioactive elastin-like-recombinamers induce bone regeneration

Kampleitner Carina , Hildebrand Gerhard , Liefeith Klaus , Gonzalez Constancio , Rodriguez-Cabello Jose Carlos , Markus Andrea , Dullin Christian , Alves Frauke , Hoffmann Oskar

Non-healing fractures caused by trauma, disease or tumour resection demand the use of bone grafts to support and stimulate the healing process. We sought to develop and evaluate the effect of a novel bioactive biodegradable biomaterial designed to fill large bone lesions and to improve bone healing. We used two-photon polymerised synthetic polymer scaffolds composed of lactide (LA), caprolactone (CL), and methacrylate (MA) with varying LA: CL ratio and percentage of methacryla...

ba0005p233 | Genetics and Epigenetics | ECTS2016

Differentially methylated regions in gene enhancers of mesenchymal stem cells from osteoporotic patients

Del Real Alvaro , Perez-Campo Flor , Sanudo Carolina , Garces Carlos , Garcia-Ibarbia Carmen , Perez-Nunez Maria I. , Riancho Jose A.

Osteoporosis (OP) is characterised by reduced bone mass, due to an insufficient osteoblast-mediated bone formation, unable to replace the bone tissue removed by osteoclasts. Mesenchymal stem cells (MSCs) are multipotent cells capable of differentiating into osteoblasts, adipocytes and chondrocytes. Epigenetic marks like DNA methylation could influence the differentiation potential of these cells into osteoblasts and, consequently, the risk of OP. To explore this hypothesis, we...